To counteract this immune checkpoint mechanism, CD47 antagonists have been developed to disrupt CD47-SIRPα interactions, thereby potentiating macrophage-mediated tumor clearance and enhancing ferroptosis-based immunotherapy. Here, CD47 is linked to neoplasm.